Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Monopar Therapeutics Q3 2026 Results: Net Loss of $6.2M, Loss Widens

Monopar Therapeutics is a clinical-stage biopharmaceutical company focused on radiopharmaceuticals and copper-chelating therapies like ALXN1840. For the nine months ended September 30, 2026, the company reported 6,776,773 shares of common stock outstanding and continues to incur significant losses as it prepares a rolling NDA submission for ALXN1840.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Net income-6.2-3.4
EPS (diluted, $ a share)$-0.72$-0.48

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: MNPR. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Monopar Therapeutics: key numbers

Share price
$71.06Close, Nov 17
Market cap
$482M
Shares outstanding
6.78MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Monopar Therapeutics

All →
8:01 AM ET 8-K
Financial Results

Monopar Therapeutics Financial Results

Monopar Therapeutics reported third quarter 2026 financial results, including a net loss of $6.2 million and a cash position of $129.4 million. The company highlighted progress on its rolling NDA submission for ALXN1840 in Wilson disease, which it expects to complete within the next several weeks.

8:16 PM ET Form 4
Insider Selling

Monopar Therapeutics Insider Raymond Anderson Sells $215K of Stock

Raymond Anderson sold 3,142 shares of Monopar Therapeutics at $66.16 to $70.04 a share (average $68.35) in 4 transactions, worth $215K in total on Nov 2, 2026. Shares held after the trade: 5,373 (-21.8%).

Value
$215K
Shares
3,142
Average price
$68.35
Holding change
-21.8%
Trade date
Nov 2, 2026
8:15 PM ET Form 4
Insider Selling

Monopar Therapeutics Insider Kim R. Tsuchimoto Sells $290K of Stock

Kim R. Tsuchimoto sold 4,090 shares of Monopar Therapeutics at $70.10 to $72.21 a share (average $70.92) in 4 transactions, worth $290K in total between Nov 2, 2026 and Nov 4, 2026. Shares held after the trade: 0 (-100.0%).

Value
$290K
Shares
4,090
Average price
$70.92
Holding change
-100.0%
Trade date
Nov 2, 2026 to Nov 4, 2026
5:43 PM ET Form 4
Insider Selling

Monopar Therapeutics Insider Christopher M. Starr Sells $659K of Stock

Christopher M. Starr sold 8,400 shares of Monopar Therapeutics at $78.09 to $79.67 a share (average $78.50) in 3 transactions, worth $659K in total on Oct 1, 2026. Shares held after the trade: 5,173 (-13.4%).

Value
$659K
Shares
8,400
Average price
$78.50
Holding change
-13.4%
Trade date
Oct 1, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.